CD8A and neoplasm: Our data revealed that in cinobufagin-treated animals, tumor infiltrating lymphocytes (CD3+, CD8+, CD4+) levels were largely increased in xenograft tumors, indicating intra-tumoral inflammation might play a role in cinobufagin-induced cancer pain release.